Pressefach: Capsulution Pharma AG

Improved monitoring of blood glucose for diabetes patients

Eyesense and Capsulution sign development contract

(PresseBox) Berlin, 30.06.2006, The swiss company Eyesense AG and the Berlin based Capsulution Nanoscience AG have recently signed a development contract aiming at the development of innovative and more user friendly products for diabetes patients to monitor blood sugar levels.

These products for a pain free and more reliable measurement of blood sugar levels are being developed under the direction of Eyesense AG. “The new product eases the procedure for frequent blood glucose level measures and helps diabetes patients to control and maintain healthy blood glucose levels.”, said Dr. Peter Herbrechtsmeier, CEO of Eyesense. Thereby common sequela of diabetes, for example cardiovascular disease or loss of sight, can be reduced.

Both companies count on their long experience in joint developmental work. Capsulution makes a major contribution to the product by taking advantage of its tunable nano-capsules. The biocompatible capsules ensure the measurement of the blood glucose near the human eye. The frequent measurement of the blood sugar concentration is performed by a special portable measuring instrument developed by Eyesense.


About Eyesense AG:
EyeSense AG is a venture-backed diagnostic device company based in Basel and operations close to Frankfurt a. Main, Germany. Eyesense was founded in 2006 as a spin-out from Ciba Vision AG (a Novartis company) and develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. In addition to glucose, the testing platform being developed by Eyesense has the potential to measure a broad variety of medical-relevant analytes in patients.

About Capsulution Pharma AG

Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company implements its worldwide-patented LBL Technology®. Based on their minute size, their functionality and their highly reproducible production process, the tunable capsules can be used in a multitude of different applications. Accordingly, the precision-sized capsules can be made to function in a manner suited to the intended application, and can be given biochemical, electrical, optical and magnetic properties tailored to the individual customer. In order to meet customers’ needs for complete product solutions, Capsulution designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL units. In 2005, the renowned growth consultants Frost & Sullivan awarded the year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

Further press release of this company

• 22.02.2010 - Into the future with a stronger team
• 17.11.2008 - Capsulution and NanoDel merge their businesses
• 17.11.2008 - Capsulution und NanoDel schließen sich zu Capsulution Pharma...
• 21.07.2008 - MIDAS Pharma und Capsulution unterzeichnen Kooperationsvertrag
• 21.07.2008 - MIDAS Pharma and Capsulution sign Cooperation Contract
• 14.07.2008 - Advanced Materials Technology und Capsulution NanoScience AG...